



## Clinical trial results:

### **LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co-Administered with and without Low-Dose Estradiol and Norethindrone Acetate in Women with Heavy Menstrual Bleeding Associated with Uterine Fibroids**

#### **Summary**

EudraCT number	2016-003727-27
Trial protocol	GB DE PL IT
Global end of trial date	29 April 2019

#### **Results information**

Result version number	v1 (current)
This version publication date	12 June 2020
First version publication date	12 June 2020

#### **Trial information**

##### **Trial identification**

Sponsor protocol code	MVT-601-3001
-----------------------	--------------

##### **Additional study identifiers**

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT03049735
WHO universal trial number (UTN)	-

Notes:

##### **Sponsors**

Sponsor organisation name	Myovant Sciences GmbH
Sponsor organisation address	Viaduktstrasse 8, Basel, Switzerland, 4051
Public contact	Clinical Trials at Myovant, Myovant Sciences GmbH, +1 650 238 0250, clinicaltrials@myovant.com
Scientific contact	Senior VP of Clinical Development, Myovant Sciences GmbH, +1 650 238 0250, LIBERTY@myovant.com

Notes:

##### **Paediatric regulatory details**

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

## Results analysis stage

Analysis stage	Final
Date of interim/final analysis	31 January 2020
Is this the analysis of the primary completion data?	Yes
Primary completion date	29 April 2019
Global end of trial reached?	Yes
Global end of trial date	29 April 2019
Was the trial ended prematurely?	No

Notes:

## General information about the trial

Main objective of the trial:

To determine the benefit of relugolix 40 milligrams (mg) once a day co-administered with estradiol (E2) 1 mg and norethindrone acetate (NETA) 0.5 mg compared with placebo for 24 weeks on heavy menstrual bleeding associated with uterine fibroids.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonisation (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	07 March 2017
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

## Population of trial subjects

### Subjects enrolled per country

Country: Number of subjects enrolled	United States: 298
Country: Number of subjects enrolled	Brazil: 11
Country: Number of subjects enrolled	Italy: 20
Country: Number of subjects enrolled	Poland: 50
Country: Number of subjects enrolled	South Africa: 7
Country: Number of subjects enrolled	United Kingdom: 2
Worldwide total number of subjects	388
EEA total number of subjects	72

Notes:

### Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0

Adolescents (12-17 years)	0
Adults (18-64 years)	388
From 65 to 84 years	0
85 years and over	0

## Subject disposition

### Recruitment

Recruitment details:

A total of 80 study centers globally were initiated in this study, including centers in the United States, Brazil, Italy, Poland, South Africa, and the United Kingdom.

### Pre-assignment

Screening details:

A total of 388 premenopausal women aged 18 to 50 years with heavy menstrual bleeding ( $\geq 80$  mL per cycle for two cycles or  $\geq 160$  milliliters (mL) during one cycle documented by the alkaline hematin method) associated with uterine fibroids were randomized. One placebo participant was randomized and not treated due to a serious adverse event.

### Period 1

Period 1 title	Treatment (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator, Monitor

### Arms

Are arms mutually exclusive?	Yes
<b>Arm title</b>	Relugolix plus E2/NETA (Group A)

Arm description:

Relugolix co-administered with E2/NETA for 24 weeks.

Arm type	Experimental
Investigational medicinal product name	Relugolix
Investigational medicinal product code	
Other name	TAK-385, MVT-601
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Relugolix (40 mg) tablet administered orally once daily for 24 weeks.

Investigational medicinal product name	Estradiol/Norethindrone Acetate
Investigational medicinal product code	
Other name	E2/NETA, low-dose hormonal add-back
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily for 24 weeks.

<b>Arm title</b>	Relugolix plus Delayed E2/NETA (Group B)
------------------	--

Arm description:

Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.

Arm type	Experimental
Investigational medicinal product name	Relugolix
Investigational medicinal product code	
Other name	TAK-385, MVT-601
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Relugolix (40 mg) tablet co-administered with E2 (0 mg)/NETA (0 mg) placebo capsule for 12 weeks

followed by relugolix (40 mg) tablet co-administered with E2 (1.0 mg)/NETA (0.5 mg) capsule for 12 weeks.

Investigational medicinal product name	Estradiol/Norethindrone Acetate
Investigational medicinal product code	
Other name	E2/NETA, low-dose hormonal add-back
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

E2 (1.0 mg)/NETA (0.5 mg) co-formulated capsule administered orally once daily for 12 weeks.

Investigational medicinal product name	Estradiol/Norethindrone Acetate Placebo
Investigational medicinal product code	
Other name	E2/NETA, low-dose hormonal add-back placebo
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily for 12 weeks.

<b>Arm title</b>	Placebo (Group C)
------------------	-------------------

Arm description:

Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.

Arm type	Placebo
Investigational medicinal product name	Relugolix Placebo
Investigational medicinal product code	
Other name	TAK-385 Placebo, MVT-601 Placebo
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

Relugolix (0 mg) placebo tablet administered orally once daily for 24 weeks.

Investigational medicinal product name	Estradiol/Norethindrone Acetate Placebo
Investigational medicinal product code	
Other name	E2/NETA, low-dose hormonal add-back placebo
Pharmaceutical forms	Capsule
Routes of administration	Oral use

Dosage and administration details:

E2 (0 mg)/NETA (0 mg) placebo capsule administered orally once daily for 24 weeks.

Number of subjects in period 1	Relugolix plus E2/NETA (Group A)	Relugolix plus Delayed E2/NETA (Group B)	Placebo (Group C)
Started	128	132	128
Received at Least 1 Dose of Study Drug	128	132	127
Completed	100	103	105
Not completed	28	29	23
Consent withdrawn by subject	10	3	7
Did not receive any study drug	-	-	1
Adverse event, non-fatal	7	18	5
Other	5	3	1

Pregnancy	-	-	1
Lost to follow-up	1	5	5
Protocol deviation	1	-	-
Lack of efficacy	4	-	3

## Baseline characteristics

### Reporting groups

Reporting group title	Relugolix plus E2/NETA (Group A)
Reporting group description: Relugolix co-administered with E2/NETA for 24 weeks.	
Reporting group title	Relugolix plus Delayed E2/NETA (Group B)
Reporting group description: Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.	
Reporting group title	Placebo (Group C)
Reporting group description: Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.	

Reporting group values	Relugolix plus E2/NETA (Group A)	Relugolix plus Delayed E2/NETA (Group B)	Placebo (Group C)
Number of subjects	128	132	128
Age categorical Units: Subjects			

Age continuous Units: years			
arithmetic mean	42.5	41.3	42.2
standard deviation	± 4.99	± 5.39	± 5.70
Gender categorical Units: Subjects			
Female	128	132	128
Male	0	0	0
Geographic Region Units: Subjects			
North America	98	101	99
Rest of World	30	31	29
Race Units: Subjects			
American Indian or Alaska Native	2	5	1
Asian	0	2	2
Black or African American	59	67	66
Native Hawaiian or Other Pacific Islander	0	0	0
White	64	53	56
Other	2	1	1
Multiple	1	4	2
Ethnicity (NIH/OMB) Units: Subjects			
Not Hispanic or Latino	92	99	104
Hispanic or Latino	34	33	23
Not reported	2	0	1

Mean MBL volume			
Units: mL			
arithmetic mean	239.44	228.89	218.76
standard deviation	± 180.292	± 159.623	± 125.039

<b>Reporting group values</b>	Total		
Number of subjects	388		
Age categorical			
Units: Subjects			

Age continuous			
Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical			
Units: Subjects			
Female	388		
Male	0		
Geographic Region			
Units: Subjects			
North America	298		
Rest of World	90		
Race			
Units: Subjects			
American Indian or Alaska Native	8		
Asian	4		
Black or African American	192		
Native Hawaiian or Other Pacific Islander	0		
White	173		
Other	4		
Multiple	7		
Ethnicity (NIH/OMB)			
Units: Subjects			
Not Hispanic or Latino	295		
Hispanic or Latino	90		
Not reported	3		
Mean MBL volume			
Units: mL			
arithmetic mean			
standard deviation	-		

### Subject analysis sets

Subject analysis set title	Baseline Analysis Population
Subject analysis set type	Modified intention-to-treat
Subject analysis set description:	
All participants who were randomized to treatment and who received at least 1 dose of study drug.	



<b>Reporting group values</b>	Baseline Analysis Population		
Number of subjects	387		
Age categorical Units: Subjects			
Age continuous Units: years arithmetic mean standard deviation	42.0 ± 5.38		
Gender categorical Units: Subjects			
Female Male	387 0		
Geographic Region Units: Subjects			
North America Rest of World	297 90		
Race Units: Subjects			
American Indian or Alaska Native Asian Black or African American Native Hawaiian or Other Pacific Islander White Other Multiple	8 4 191 0 173 4 7		
Ethnicity (NIH/OMB) Units: Subjects			
Not Hispanic or Latino Hispanic or Latino Not reported	294 90 3		
Mean MBL volume Units: mL arithmetic mean standard deviation	229.05 ± 156.576		

## End points

### End points reporting groups

Reporting group title	Relugolix plus E2/NETA (Group A)
Reporting group description: Relugolix co-administered with E2/NETA for 24 weeks.	
Reporting group title	Relugolix plus Delayed E2/NETA (Group B)
Reporting group description: Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.	
Reporting group title	Placebo (Group C)
Reporting group description: Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.	
Subject analysis set title	Baseline Analysis Population
Subject analysis set type	Modified intention-to-treat
Subject analysis set description: All participants who were randomized to treatment and who received at least 1 dose of study drug.	

### Primary: Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA

End point title	Percentage Of Participants Who Achieved A Menstrual Blood Loss (MBL) Volume Of < 80 mL And A ≥ 50% Reduction From Baseline MBL Volume With Relugolix Plus E2/NETA <sup>[1]</sup>
-----------------	--

#### End point description:

A responder was a participant who had MBL volume of < 80 mL and at least a 50% reduction from baseline MBL volume over the last 35 days of treatment (up to Week 24). All returned feminine products collected at each clinical visit were analyzed by the alkaline hematin method to obtain the MBL volume. MBL volume was measured over the Week 24/early termination feminine product collection interval (up to 35 days prior to the last dose of treatment). The percentage of participants who were responders are presented.

End point type	Primary
----------------	---------

#### End point timeframe:

From Baseline up to last 35 days of treatment (up to Week 24)

#### Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per the objective of the study, the pre-specified primary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128 <sup>[2]</sup>	127 <sup>[3]</sup>		
Units: percentage of participants				
number (confidence interval 95%)	73.4 (64.91 to 80.85)	18.9 (12.50 to 26.80)		

#### Notes:

[2] - Modified Intention-to-Treat Population

[3] - Modified Intention-to-Treat Population

## Statistical analyses

<b>Statistical analysis title</b>	Number of responders at Week 24
Statistical analysis description: The primary efficacy analysis was the comparison of the relugolix + E2/NETA group with the placebo group with respect to responder rate.	
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)
Number of subjects included in analysis	255
Analysis specification	Pre-specified
Analysis type	superiority <sup>[4]</sup>
P-value	< 0.0001 <sup>[5]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Treatment difference
Point estimate	54.54
Confidence interval	
level	95 %
sides	2-sided
lower limit	44.3
upper limit	64.78

Notes:

[4] - Treatment difference is relugolix + E2/NETA minus placebo.

[5] - P-value was stratified by baseline MBL volume (< 225 mL or ≥ 225 mL) and geographic region (North America or Rest of World). Assessed at a two-sided  $\alpha = 0.05$  significance level.

### Secondary: Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment

End point title	Percentage Of Participants With Amenorrhea Over The Last 35 Days Of Treatment <sup>[6]</sup>
-----------------	--

End point description:

Amenorrhea was defined as meeting one of the following criteria for two consecutive visits:

1. No feminine product returned due to reported amenorrhea;
2. No feminine product returned due to reports of spotting/negligible bleeding coupled with eDiary data indicating infrequent non-cyclic bleeding/spotting;
3. Feminine product collection with a negligible observed MBL volume coupled with eDiary data indicating infrequent non-cyclic bleeding/spotting.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to last 35 days of treatment (up to Week 24)

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period. Justification: As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128 <sup>[7]</sup>	127 <sup>[8]</sup>		
Units: percentage of participants				
number (confidence interval 95%)	52.34 (43.34 to 61.24)	5.51 (2.24 to 11.03)		

Notes:

[7] - mITT Population

[8] - mITT Population

## Statistical analyses

<b>Statistical analysis title</b>	Achieved Amenorrhea with Relugolix+E2/NETA
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)
Number of subjects included in analysis	255
Analysis specification	Pre-specified
Analysis type	superiority <sup>[9]</sup>
P-value	< 0.0001 <sup>[10]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Treatment difference
Point estimate	46.83
Confidence interval	
level	95 %
sides	2-sided
lower limit	37.31
upper limit	56.35

Notes:

[9] - Treatment difference was Relugolix + E2/NETA minus Placebo. 95% CI for difference is based on the normal approximation.

[10] - P-value was based on Cochran-Mantel-Haenszel test stratified by Baseline MBL volume (< 225 mL, ≥ 225 mL) and geographic region (North America or Rest of World). Assessed at a two-sided α = 0.05 significance level.

## Secondary: Percent Change From Baseline At Week 24 In MBL Volume

End point title	Percent Change From Baseline At Week 24 In MBL Volume <sup>[11]</sup>
End point description:	MBL volume was measured using the alkaline hematin method. Least square (LS) means for test of difference is Relugolix + E2/NETA minus Placebo based on mixed-effect model with treatment, visit, region, Baseline MBL and treatment by visit interaction included as fixed effects.
End point type	Secondary
End point timeframe:	Baseline, Week 24

Notes:

[11] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	89	95		
Units: percent change				
least squares mean (confidence interval 95%)	-84.3 (-93.5 to -75.0)	-23.2 (-32.2 to -14.1)		

## Statistical analyses

<b>Statistical analysis title</b>	MBL Volume Percent Change with Relugolix + E2/NETA
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)

Number of subjects included in analysis	184
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.0001 <sup>[12]</sup>
Method	Mixed models analysis
Parameter estimate	Treatment difference
Point estimate	-61.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-73.5
upper limit	-48.6
Variability estimate	Standard error of the mean
Dispersion value	6.32

Notes:

[12] - p-value for test of difference was Relugolix + E2/NETA minus placebo based on mixed-effect model with treatment, visit, region, Baseline MBL and treatment by visit interaction included as fixed effects. Assessed at a two-sided  $\alpha = 0.05$  significance.

### **Secondary: Percentage Of Participants With A Hemoglobin Level $\leq 10.5$ g/dL At Baseline Who Achieved An Increase Of $> 2$ g/dL From Baseline At Week 24**

End point title	Percentage Of Participants With A Hemoglobin Level $\leq 10.5$ g/dL At Baseline Who Achieved An Increase Of $> 2$ g/dL From Baseline At Week 24 <sup>[13]</sup>
-----------------	---

End point description:

Blood samples were collected from participants for hemoglobin measurements .Percentages are based on number of participants with hemoglobin  $\leq 10.5$  gram (g)/deciliter (dL) at Baseline and reported at Week 24.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 24

Notes:

[13] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA with placebo arms are presented.

<b>End point values</b>	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	30	23		
Units: percentage of participants				
number (confidence interval 95%)	50.0 (31.30 to 68.70)	21.74 (7.46 to 43.70)		

### **Statistical analyses**

<b>Statistical analysis title</b>	Change in Hemoglobin with Relugolix+E2/NETA
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)

Number of subjects included in analysis	53
Analysis specification	Pre-specified
Analysis type	superiority <sup>[14]</sup>
P-value	= 0.0377 <sup>[15]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Treatment difference
Point estimate	28.26
Confidence interval	
level	95 %
sides	2-sided
lower limit	3.68
upper limit	52.84

Notes:

[14] - Treatment difference is Relugolix + E2/NETA minus Placebo. 95% CI for difference is based on the normal approximation.

[15] - P-value is based on Cochran-Mantel-Haenszel test stratified by Baseline MBL volume (< 225 mL, >= 225 mL).

Assessed at a two-sided  $\alpha = 0.05$  significance level.

### Secondary: Percentage Of Participants With A Maximum NRS Score $\leq 1$ For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment

End point title	Percentage Of Participants With A Maximum NRS Score $\leq 1$ For Uterine Fibroid-Associated Pain Over The Last 35 Days Of Treatment <sup>[16]</sup>
-----------------	---

End point description:

Uterine fibroid-associated pain was assessed by a pain numerical rating scale (NRS). The pain NRS is a validated, single-item, self-reported measure, which asks respondents to rank their pain on an 11-point scale as follows: 0 (no pain), 1 to 3 (mild pain), 4 to 6 (moderate pain), and 7 to 10 (severe pain). Participants were asked to document, in an electronic diary, the worst pain associated with their uterine fibroids that they experienced during the last 24 hours, every day until the end of study drug administration. Pain evaluable participants, defined as those who had maximum NRS score  $\geq 4$  at baseline and had at least 28 days (80% of the last 35 days of treatment) of pain scores recorded in the e-Diary, were analyzed.

End point type	Secondary
----------------	-----------

End point timeframe:

From Baseline up to Week 24

Notes:

[16] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	58	69		
Units: Percentage of Participants				
number (confidence interval 95%)	43.10 (30.16 to 56.77)	10.14 (4.18 to 19.79)		

### Statistical analyses

<b>Statistical analysis title</b>	Pain Assessment with Relugolix+E2/NETA
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)
Number of subjects included in analysis	127
Analysis specification	Pre-specified
Analysis type	superiority <sup>[17]</sup>
P-value	< 0.0001 <sup>[18]</sup>
Method	Cochran-Mantel-Haenszel
Parameter estimate	Treatment difference
Point estimate	32.96
Confidence interval	
level	95 %
sides	2-sided
lower limit	18.36
upper limit	47.56

Notes:

[17] - Treatment difference is Relugolix + E2/NETA minus Placebo. 95% CI for difference is based on the normal approximation.

[18] - P-value is based on Cochran-Mantel-Haenszel test stratified by Baseline MBL volume (< 225 mL, >= 225 mL).

Assessed at a two-sided  $\alpha = 0.05$  significance level.

## Secondary: Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume

End point title	Percent Change From Baseline At Week 24 In Primary Uterine Fibroid Volume <sup>[19]</sup>
-----------------	---

End point description:

The volume of the primary uterine fibroid was measured by transvaginal or transabdominal ultrasound. LS Means based on analysis of covariance model including treatment, randomization stratification factors, Baseline MBL volume (< 225 mL, >= 225 mL) and geographic region (North America, Rest of World), and Baseline values as covariate.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

Notes:

[19] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	94	102		
Units: percent change				
least squares mean (confidence interval 95%)	-12.4 (-23.5 to -1.4)	-0.3 (-10.9 to 10.4)		

## Statistical analyses

<b>Statistical analysis title</b>	Uterine Fibroid Volume with Relugolix+E2/NETA
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)

Number of subjects included in analysis	196
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0921 <sup>[20]</sup>
Method	ANCOVA
Parameter estimate	Treatment difference
Point estimate	-12.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-26.3
upper limit	2
Variability estimate	Standard error of the mean
Dispersion value	7.19

Notes:

[20] - Based on analysis of covariance model with treatment, randomization stratification factors, Baseline MBL volume, geographic region (North America, Rest of World), and Baseline values as covariate. Assessed at a two-sided  $\alpha = 0.05$  significance level.

### Secondary: Percent Change From Baseline At Week 24 In Uterine Volume

End point title	Percent Change From Baseline At Week 24 In Uterine
-----------------	--

End point description:

The volume of the uterus was measured by transvaginal or transabdominal ultrasound.

LS means for test of difference is Relugolix + E2/NETA minus Placebo at Week 24 is based on analysis of covariance model including treatment, randomization stratification factors, Baseline MBL volume (< 225 mL,  $\geq$  225 mL) and geographic region (North America, Rest of World), and Baseline values as covariate.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

Notes:

[21] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	97	102		
Units: percent change				
least squares mean (confidence interval 95%)	-12.9 (-19.0 to -6.9)	2.2 (-3.7 to 8.1)		

### Statistical analyses

Statistical analysis title	Uterine Volume with Relugolix+E2/NETA
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)



Number of subjects included in analysis	199
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.0002 <sup>[22]</sup>
Method	ANCOVA
Parameter estimate	Treatment difference
Point estimate	-15.1
Confidence interval	
level	95 %
sides	2-sided
lower limit	-23
upper limit	-7.3
Variability estimate	Standard error of the mean
Dispersion value	3.98

Notes:

[22] - Based on analysis of covariance model with treatment, randomization stratification factors, Baseline MBL volume, geographic region (North America, Rest of World), and Baseline values as covariate. Assessed at a two-sided  $\alpha = 0.05$  significance level.

### **Secondary: Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5)**

End point title	Change From Baseline At Week 24 In UFS-QoL Bleeding And Pelvic Discomfort Scale Score As Measured By The UFS-QoL (Q1, Q2, Q5) <sup>[23]</sup>
-----------------	---

End point description:

The Uterine Fibroid Symptom and Health-Related Quality of Life (UFS-QoL) Bleeding and Pelvic Discomfort Scale has been derived from the UFS-QoL Symptoms Scale. The scale consists of the following three symptoms proximal to uterine fibroids: Heavy bleeding during your menstrual period (Question [Q] 1), passing blood clots during your menstrual period (Q2), and feeling tightness or pressure in your pelvic area (Q5). The lowest possible raw score is 3 and the highest possible raw score is 15. The possible raw score range is 12. The following formula was used to transform the raw score to a normalized score: Transformed Score = [(Actual raw score – lowest possible raw score)/(Possible raw score range)] \* 100

Transformed score ranges from 0 to 100 based on Likert scale (None of time, a little of time, some of the time, most of the time and all of the time). Lower score indicates minimal symptom severity and higher score indicates maximum symptom severity.

End point type	Secondary
----------------	-----------

End point timeframe:

Baseline, Week 24

Notes:

[23] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary efficacy analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

<b>End point values</b>	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	97	103		
Units: units on a scale				
least squares mean (confidence interval 95%)	-45.0 (-50.7 to -39.3)	-16.1 (-21.6 to -10.5)		

## Statistical analyses

<b>Statistical analysis title</b>	UFS-QoL BPD Score with Relugolix +E2/NETA
Comparison groups	Relugolix plus E2/NETA (Group A) v Placebo (Group C)
Number of subjects included in analysis	200
Analysis specification	Pre-specified
Analysis type	superiority <sup>[24]</sup>
P-value	< 0.0001 <sup>[25]</sup>
Method	Mixed models analysis
Parameter estimate	Treatment difference
Point estimate	-28.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-36.3
upper limit	-21.5
Variability estimate	Standard error of the mean
Dispersion value	3.75

Notes:

[24] - Treatment difference is Relugolix + E2/NETA minus Placebo based on mixed-effect model with treatment, visit, region, Baseline MBL and treatment by visit interaction included as fixed effects. The multiple visits for each participant were the repeated measures as random effect within each participant and an unstructured covariance.

[25] - Assessed at a two-sided  $\alpha = 0.05$  significance level.

## Other pre-specified: Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 - L4), As Assessed By DXA

End point title	Percent Change From Baseline At Week 12 In Bone Mineral Density At The Lumbar Spine (L1 - L4), As Assessed By DXA <sup>[26]</sup>
-----------------	---

End point description:

Bone mineral density (BMD) was assessed by dual-energy x-ray absorptiometry (DXA) at the lumbar spine (L1, L2, L3, and L4) at Baseline and at Week 12. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD. The LS means were based on a mixed-effect model with visit, region, Baseline menstrual blood loss volume, age at Baseline, body mass index at Baseline, bone mineral density at Baseline, race, and treatment by visit interaction included as fixed effects.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline, Week 12

Notes:

[26] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary analyses compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12. Therefore, only the relugolix plus E2/NETA and relugolix plus delayed E2/NETA arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Relugolix plus Delayed E2/NETA (Group B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	103		
Units: percent change				
least squares mean (standard error)				

Lumbar Spine (L1-L4): Week 12	-0.470 ( $\pm$ 0.2915)	-1.995 ( $\pm$ 0.2848)		
-------------------------------	------------------------	------------------------	--	--

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 - L4), Total Hip, And Femoral Neck

End point title	Percent Change From Baseline At Week 24 In Bone Mineral Density At The Lumbar Spine (L1 - L4), Total Hip, And Femoral Neck <sup>[27]</sup>
-----------------	--

End point description:

BMD was assessed by DXA at the lumbar spine (L1, L2, L3, and L4), total hip, and femoral neck at Baseline and at Week 24. The scans were read by the central radiology laboratory in accordance with the imaging charter. The same DXA machine was used at the local imaging center at each site and operated in the same scan mode for all images procured for an individual participant. All images were submitted for central reading. The central radiology laboratory collected and evaluated all DXA scans for acceptability and measured BMD. The LS means were based on a mixed-effect model with visit, region, Baseline menstrual blood loss volume, age at Baseline, body mass index at Baseline, bone mineral density at Baseline, race, and treatment by visit interaction included as fixed effects.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline, Week 24

Notes:

[27] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	101	103		
Units: percent change				
least squares mean (standard error)				
Lumbar Spine (L1-L4)	-0.356 ( $\pm$ 0.2929)	0.052 ( $\pm$ 0.2896)		
Total Hip	0.023 ( $\pm$ 0.2461)	0.549 ( $\pm$ 0.2407)		
Femoral Neck	-0.262 ( $\pm$ 0.4466)	0.307 ( $\pm$ 0.4395)		

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12

End point title	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 12 <sup>[28]</sup>
-----------------	--

End point description:

An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term. Reported CI based on exact binomial 95% CI (Clopper-Pearson).

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Baseline through Week 12

Notes:

[28] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the secondary analysis compared relugolix plus E2/NETA with relugolix plus delayed E2/NETA at Week 12. Therefore, only the relugolix plus E2/NETA and relugolix plus delayed E2/NETA arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Relugolix plus Delayed E2/NETA (Group B)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	129		
Units: percentage of participants				
number (confidence interval 95%)	10.94 (6.11 to 17.67)	36.36 (28.17 to 45.18)		

## Statistical analyses

Statistical analysis title	Vasomotor Symptoms Through Week 12
Comparison groups	Relugolix plus E2/NETA (Group A) v Relugolix plus Delayed E2/NETA (Group B)
Number of subjects included in analysis	257
Analysis specification	Pre-specified
Analysis type	other <sup>[29]</sup>
P-value	< 0.0001
Method	Fisher exact
Parameter estimate	Risk ratio (RR)
Point estimate	0.3
Confidence interval	
level	95 %
sides	2-sided
lower limit	0.17
upper limit	0.52

Notes:

[29] - Relative risk ratio is relugolix plus E2/NETA over relugolix plus delayed E2/NETA.

## Other pre-specified: Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24

End point title	Percentage Of Participants Experiencing Vasomotor Symptoms Through Week 24 <sup>[30]</sup>
-----------------	--

---

**End point description:**

An adverse event was defined as an unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product, whether or not related to the medicinal product. The preferred terms of hyperhidrosis, feeling hot, hot flush, night sweats, and flushing were combined to describe vasomotor symptoms. Participants with multiple events for a given preferred term were counted only once for each preferred term. Reported percentages based on the total number of patients in each treatment group.

---

End point type	Other pre-specified
----------------	---------------------

---

End point timeframe:

Baseline through Week 24

---

**Notes:**

[30] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, the pre-specified secondary analyses compared relugolix plus E2/NETA with placebo. Therefore, only relugolix plus E2/NETA and placebo arms are presented.

End point values	Relugolix plus E2/NETA (Group A)	Placebo (Group C)		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	128	127		
Units: percentage of participants				
number (not applicable)	14.8	9.4		

---

**Statistical analyses**

No statistical analyses for this end point

---

---

**Other pre-specified: Predose Trough Concentrations Of Relugolix And Norethindrone In The Relugolix Plus E2/NETA Group At Week 24**

---

End point title	Predose Trough Concentrations Of Relugolix And Norethindrone In The Relugolix Plus E2/NETA Group At Week 24 <sup>[31]</sup>
-----------------	---

---

**End point description:**

Blood samples for determination of relugolix and Norethindrone (NET) plasma concentrations were collected predose at Week 24. On clinic visit days, participants were instructed to hold their dose of study drug until blood samples for determination of plasma drug concentrations were collected at the clinic and to record the time of their previous dose (that is, the time they took their dose on the day before the clinic visit). Relugolix and NET plasma concentrations were determined using validated bioanalytical methodology.

The lower limit of quantification for relugolix and NET plasma concentrations were both 0.05 nanograms/milliliter (ng/mL). Concentrations below the quantification limit (BQL) were set to 0 for analysis of summary statistics.

---

End point type	Other pre-specified
----------------	---------------------

---

End point timeframe:

Week 24

---

**Notes:**

[31] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, only relugolix plus E2/NETA concentrations are presented.

End point values	Relugolix plus E2/NETA (Group A)			
Subject group type	Reporting group			
Number of subjects analysed	92			
Units: ng/mL				
arithmetic mean (standard deviation)				
Relugolix (n=92)	2.13 (± 2.144)			
NET (n=91)	0.33 (± 0.369)			

## Statistical analyses

No statistical analyses for this end point

## Other pre-specified: Predose Trough Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group At Week 24

End point title	Predose Trough Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group At Week 24 <sup>[32]</sup>
-----------------	---

End point description:

Blood samples for determination of estradiol serum concentrations were collected predose at Baseline and Week 24. On clinic visit days, participants were instructed to hold their dose of study drug until blood samples for determination of serum concentrations were collected at the clinic and to record the time of their previous dose (that is, the time they took their dose on the day before the clinic visit). Summary data for estradiol trough serum concentrations are descriptive only and values were not baseline-adjusted, which is an approach that has been employed for assessment of endogenously-produced substances upon exogenous administration. Estradiol serum concentrations were determined using validated bioanalytical methodology. The lower limit of quantification for estradiol serum concentration was 2.5 picograms (pg)/mL. Concentrations BQL were set to 0 for analysis of summary statistics.

End point type	Other pre-specified
----------------	---------------------

End point timeframe:

Week 24

Notes:

[32] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, only relugolix plus E2/NETA concentrations are presented.

End point values	Relugolix plus E2/NETA (Group A)			
Subject group type	Reporting group			
Number of subjects analysed	91			
Units: pg/mL				
arithmetic mean (standard deviation)	48.34 (± 59.660)			

## Statistical analyses

No statistical analyses for this end point

---

**Other pre-specified: Change From Baseline At Week 24 In Predose Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group**

---

End point title	Change From Baseline At Week 24 In Predose Concentrations Of Estradiol In The Relugolix Plus E2/NETA Group <sup>[33]</sup>
-----------------	--

**End point description:**

Blood samples for determination of estradiol concentrations were collected predose at Baseline and at Weeks 4, 12, and 24 and were analyzed at a central laboratory using a standard, validated clinical methodology. For pharmacokinetic analysis of estradiol, a separate pharmacokinetic sample was obtained to be analyzed at the bioanalytical laboratory. The lower limit of quantification for estradiol was 19 pg/mL. Concentrations BQL were set to 0 for analysis of summary statistics. Data reported as pg/mL.

End point type	Other pre-specified
----------------	---------------------

**End point timeframe:**

Baseline, Week 24

**Notes:**

[33] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.

Justification: As per the objective of the study, only relugolix plus E2/NETA concentrations were are presented.

<b>End point values</b>	Relugolix plus E2/NETA (Group A)			
Subject group type	Reporting group			
Number of subjects analysed	91			
Units: pg/mL				
arithmetic mean (standard deviation)	-22.95 (± 84.005)			

---

**Statistical analyses**

---

No statistical analyses for this end point

## Adverse events

### Adverse events information

Timeframe for reporting adverse events:

From Day 1 to End of Study (24 Weeks)

Assessment type	Systematic
-----------------	------------

### Dictionary used

Dictionary name	MedDRA
-----------------	--------

Dictionary version	22.0
--------------------	------

### Reporting groups

Reporting group title	Relugolix plus E2/NETA (Group A)
-----------------------	----------------------------------

Reporting group description:

Relugolix co-administered with E2/NETA for 24 weeks.

Reporting group title	Relugolix plus Delayed E2/NETA (Group B)
-----------------------	--

Reporting group description:

Relugolix co-administered with E2/NETA placebo for 12 weeks, followed by relugolix co-administered with E2/NETA for 12 weeks.

Reporting group title	Placebo (Group C)
-----------------------	-------------------

Reporting group description:

Relugolix placebo co-administered with E2/NETA placebo for 24 weeks.

<b>Serious adverse events</b>	Relugolix plus E2/NETA (Group A)	Relugolix plus Delayed E2/NETA (Group B)	Placebo (Group C)
Total subjects affected by serious adverse events			
subjects affected / exposed	7 / 128 (5.47%)	3 / 132 (2.27%)	2 / 127 (1.57%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
Uterine myoma expulsion			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Uterine leiomyoma			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
Avulsion fracture			



subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Ankle fracture			
subjects affected / exposed	1 / 128 (0.78%)	1 / 132 (0.76%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Eye disorders			
Vitreous detachment			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Reproductive system and breast disorders			
Menorrhagia			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pelvic pain			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
Haematemesis			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
Panic attack			
subjects affected / exposed	0 / 128 (0.00%)	1 / 132 (0.76%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Acute psychosis			

subjects affected / exposed	0 / 128 (0.00%)	0 / 132 (0.00%)	1 / 127 (0.79%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
Hypothyroidism			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
Rhabdomyolysis			
subjects affected / exposed	1 / 128 (0.78%)	0 / 132 (0.00%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
Appendicitis			
subjects affected / exposed	0 / 128 (0.00%)	1 / 132 (0.76%)	0 / 127 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Pneumonia			
subjects affected / exposed	0 / 128 (0.00%)	0 / 132 (0.00%)	1 / 127 (0.79%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Frequency threshold for reporting non-serious adverse events: 5 %

<b>Non-serious adverse events</b>	Relugolix plus E2/NETA (Group A)	Relugolix plus Delayed E2/NETA (Group B)	Placebo (Group C)
Total subjects affected by non-serious adverse events			
subjects affected / exposed	77 / 128 (60.16%)	95 / 132 (71.97%)	84 / 127 (66.14%)
Vascular disorders			
Hot flush			
subjects affected / exposed	14 / 128 (10.94%)	47 / 132 (35.61%)	10 / 127 (7.87%)
occurrences (all)	14	48	10
Hypertension			

subjects affected / exposed occurrences (all)	7 / 128 (5.47%) 8	3 / 132 (2.27%) 5	0 / 127 (0.00%) 0
Nervous system disorders Headache subjects affected / exposed occurrences (all)	14 / 128 (10.94%) 15	14 / 132 (10.61%) 18	19 / 127 (14.96%) 20
Respiratory, thoracic and mediastinal disorders Cough subjects affected / exposed occurrences (all)	1 / 128 (0.78%) 1	0 / 132 (0.00%) 0	7 / 127 (5.51%) 7
Musculoskeletal and connective tissue disorders Arthralgia subjects affected / exposed occurrences (all)	4 / 128 (3.13%) 6	7 / 132 (5.30%) 8	4 / 127 (3.15%) 5
Infections and infestations Upper respiratory tract infection subjects affected / exposed occurrences (all)	1 / 128 (0.78%) 1	7 / 132 (5.30%) 7	3 / 127 (2.36%) 4

## More information

### Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? No

---

### Interruptions (globally)

Were there any global interruptions to the trial? No

### Limitations and caveats

None reported